Evidence map›Paper›PMID 27738177›Full record

ArticleNeuro-oncology2016

Biomarkers in NOA-04: another piece to the puzzle.

Andrew B Lassman, Timothy F Cloughesy

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Management of Low-Grade Gliomas.Cancer journal (Sudbury, Mass.)
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Andrew B LassmanDepartment of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York (A.B.L.); Neuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (T.F.C.) ABL7@cumc.columbia.edu tcloughesy@mednet.ucla.edu.
Timothy F CloughesyDepartment of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York (A.B.L.); Neuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California (T.F.C.).

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Columbia University NCI Community Oncology Research ProgramUG1CA189960 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jennifer E. Amengual, Lisa A. Kachnic · 2014 to 2026
$12.7M
NCI NIH HHS P30 CA013696NCI NIH HHS UG1 CA189960
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiomarkersHumansBiomarkers

Identifiers

PMID27738177
PMCPMC5063524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.